Head and Neck Cancer Clinical Trial
Official title:
Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill
tumor cells. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving combination chemotherapy together with radiation therapy, with
or without lapatinib, before surgery may make the tumor smaller and reduce the amount of
normal tissue that needs to be removed or eliminate the need for surgery.
PURPOSE: This phase I/II trial is studying the side effects and best dose of combination
chemotherapy given together with radiation therapy with or without lapatinib and to see how
well it works in treating patients with locally advanced cancer of the larynx or hypopharynx.
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and recommended dose for phase II of lapatinib
ditosylate in patients with locally advanced squamous cell carcinoma of the larynyx or
hypopharynx who are concomitantly treated with neoadjuvant induction chemotherapy
comprising docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy
comprising carboplatin and radiotherapy. (Phase I)
- To document the feasibility, in the framework of an organ preservation program, of this
regimen in these patients. (Phase II)
Secondary
- To look at the role of PET in patients with N1-3 disease, in terms of PET being used as
a reliable method to spare patients from planned neck dissection. (Phase II)
OUTLINE: This is a multicenter, dose-escalation phase I study followed by a randomized phase
II study. Patients are stratified by institution and EGFR status (negative vs positive).
- Phase I:
- Neoadjuvant chemotherapy: Patients receive neoadjuvant chemotherapy comprising
docetaxel IV and cisplatin IV on day 1 and fluorouracil IV continuously on days
1-5. Treatment repeats every 21 days for up to 4 courses in the absence of disease
progression or unacceptable toxicity. Patients with a complete or partial response
after 4 courses of neoadjuvant chemotherapy proceed to chemoradiotherapy. Patients
with less than a partial response after course 2 or course 4 proceed to surgery,
including total laryngectomy.
- Chemoradiotherapy: Within 3 weeks after completion of neoadjuvant chemotherapy,
patients undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and
43-47 and receive carboplatin IV on days 1, 8, 15, 22, 29, 36, and 43.
- Concurrent lapatinib ditosylate: Patients receive oral lapatinib ditosylate once
daily during neoadjuvant chemotherapy, during the break between neoadjuvant
chemotherapy and chemoradiotherapy, and during chemoradiotherapy.
- Phase II: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive neoadjuvant chemotherapy and undergo chemoradiotherapy as
in phase I.
- Arm II: Patients receive neoadjuvant chemotherapy and undergo chemoradiotherapy as
in phase I. Patients also receive concurrent lapatinib ditosylate as in phase I at
the recommended dose determined in phase I.
In both phases, treatment continues in the absence of disease progression or unacceptable
toxicity.
Patients with node-positive disease (initially) undergo tumor and blood sample collection for
biological studies. Samples are analyzed for ErbB-related activation via
immunohistochemistry, in situ hybridization, and PCR/sequencing of genes/proteins, to detect
DNA amplification and polysomy (for AKT, ErbB2, EGFR) and genomic losses (for PTEN) via FISH,
and the ratio between EGFR and EGFRvIII via QRT-PCR. Patients with node-positive disease
undergo at least elective neck dissection to evaluate the negative predictive value of PET
scanning.
Patients are followed every 3 months for one year and then every 6 months thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |